Company / Accounts Receivable
Harmony Biosciences Holdings, Inc. Accounts Receivable History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$96.8M
FY2025
5-year range
$34.8M / $96.8M
FY2021-FY2025
Trend
+16.6%
vs FY2024
Sector context
#57 of 115
Health Care
What the data says
At $97M, Harmony Biosciences Holdings, Inc.'s accounts receivable ranks #57 of 115 in the Health Care sector. Accounts Receivable has increased for 6 consecutive years, from $4M in FY2019 to $97M in FY2025.
Based on SEC 10-K filings.
$97M in FY2025 with a 5-year CAGR of +34.3%.
Improved from $74M to $97M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +20.9%
- 5-Year CAGR
- +34.3%
- 10-Year CAGR
- -
Sector benchmark
#57 of 115 in Health CareTop 50% of 115This company $96.8M Sector average $1.1B
▼
-91.3% below sector average
Key checks
Key Insights
- Harmony Biosciences Holdings, Inc.'s accounts receivable has grown for 6 consecutive years.
- 5-year CAGR of +34.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 16.6% year-over-year.
- Ranks #57 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $96.8M | +16.6% |
| FY2024 | $83.0M | +12.0% |
| FY2023 | $74.1M | +35.4% |
| FY2022 | $54.7M | +57.1% |
| FY2021 | $34.8M | +57.1% |
| FY2020 | $22.2M | +421.2% |
| FY2019 | $4.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026